533 related articles for article (PubMed ID: 34902516)
1. To PEGylate or not to PEGylate: Immunological properties of nanomedicine's most popular component, polyethylene glycol and its alternatives.
Shi D; Beasock D; Fessler A; Szebeni J; Ljubimova JY; Afonin KA; Dobrovolskaia MA
Adv Drug Deliv Rev; 2022 Jan; 180():114079. PubMed ID: 34902516
[TBL] [Abstract][Full Text] [Related]
2. DePEGylation strategies to increase cancer nanomedicine efficacy.
Kong L; Campbell F; Kros A
Nanoscale Horiz; 2019 Mar; 4(2):378-387. PubMed ID: 32254090
[TBL] [Abstract][Full Text] [Related]
3. Role of stealth lipids in nanomedicine-based drug carriers.
Rastogi M; Saha RN; Alexander A; Singhvi G; Puri A; Dubey SK
Chem Phys Lipids; 2021 Mar; 235():105036. PubMed ID: 33412151
[TBL] [Abstract][Full Text] [Related]
4. Polyethylene glycol (PEG): The nature, immunogenicity, and role in the hypersensitivity of PEGylated products.
Ibrahim M; Ramadan E; Elsadek NE; Emam SE; Shimizu T; Ando H; Ishima Y; Elgarhy OH; Sarhan HA; Hussein AK; Ishida T
J Control Release; 2022 Nov; 351():215-230. PubMed ID: 36165835
[TBL] [Abstract][Full Text] [Related]
5. Poly(ethylene glycol)-block-poly(ε-caprolactone)-and phospholipid-based stealth nanoparticles with enhanced therapeutic efficacy on murine breast cancer by improved intracellular drug delivery.
He X; Li L; Su H; Zhou D; Song H; Wang L; Jiang X
Int J Nanomedicine; 2015; 10():1791-804. PubMed ID: 25784805
[TBL] [Abstract][Full Text] [Related]
6. Detection of Pre-Existing Antibodies to Polyethylene Glycol and PEGylated Liposomes in Human Serum.
Neun BW; Dobrovolskaia MA
Methods Mol Biol; 2024; 2789():185-192. PubMed ID: 38507004
[TBL] [Abstract][Full Text] [Related]
7. Polyethylene glycol (PEG) as a broad applicability marker for LC-MS/MS-based biodistribution analysis of nanomedicines.
Hyldbakk A; Hansen T; Hak S; Borgos SEF
J Control Release; 2024 Feb; 366():611-620. PubMed ID: 38215988
[TBL] [Abstract][Full Text] [Related]
8. In vivo Studies on Pharmacokinetics, Toxicity and Immunogenicity of Polyelectrolyte Nanocapsules Functionalized with Two Different Polymers: Poly-L-Glutamic Acid or PEG.
Karabasz A; Szczepanowicz K; Cierniak A; Mezyk-Kopec R; Dyduch G; Szczęch M; Bereta J; Bzowska M
Int J Nanomedicine; 2019; 14():9587-9602. PubMed ID: 31824153
[TBL] [Abstract][Full Text] [Related]
9. Engineering poly(ethylene glycol) particles for targeted drug delivery.
Li S; Ma Y; Cui J; Caruso F; Ju Y
Chem Commun (Camb); 2024 Feb; 60(19):2591-2604. PubMed ID: 38285062
[TBL] [Abstract][Full Text] [Related]
10. Antibodies against Poly(ethylene glycol) Activate Innate Immune Cells and Induce Hypersensitivity Reactions to PEGylated Nanomedicines.
Chen WA; Chang DY; Chen BM; Lin YC; Barenholz Y; Roffler SR
ACS Nano; 2023 Mar; 17(6):5757-5772. PubMed ID: 36926834
[TBL] [Abstract][Full Text] [Related]
11. Bioinspired "Active" Stealth Magneto-Nanomicelles for Theranostics Combining Efficient MRI and Enhanced Drug Delivery.
Zhang KL; Zhou J; Zhou H; Wu Y; Liu R; Wang LL; Lin WW; Huang G; Yang HH
ACS Appl Mater Interfaces; 2017 Sep; 9(36):30502-30509. PubMed ID: 28812358
[TBL] [Abstract][Full Text] [Related]
12. Anti-PEG antibodies alter the mobility and biodistribution of densely PEGylated nanoparticles in mucus.
Henry CE; Wang YY; Yang Q; Hoang T; Chattopadhyay S; Hoen T; Ensign LM; Nunn KL; Schroeder H; McCallen J; Moench T; Cone R; Roffler SR; Lai SK
Acta Biomater; 2016 Oct; 43():61-70. PubMed ID: 27424083
[TBL] [Abstract][Full Text] [Related]
13. Lipid-polymer hybrid nanoparticles as a new generation therapeutic delivery platform: a review.
Hadinoto K; Sundaresan A; Cheow WS
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):427-43. PubMed ID: 23872180
[TBL] [Abstract][Full Text] [Related]
14. PEG-PCL-based nanomedicines: A biodegradable drug delivery system and its application.
Grossen P; Witzigmann D; Sieber S; Huwyler J
J Control Release; 2017 Aug; 260():46-60. PubMed ID: 28536049
[TBL] [Abstract][Full Text] [Related]
15. PEGylated Lipid Nanoparticle Formulations: Immunological Safety and Efficiency Perspective.
Tenchov R; Sasso JM; Zhou QA
Bioconjug Chem; 2023 Jun; 34(6):941-960. PubMed ID: 37162501
[TBL] [Abstract][Full Text] [Related]
16. PEGylation as a strategy for improving nanoparticle-based drug and gene delivery.
Suk JS; Xu Q; Kim N; Hanes J; Ensign LM
Adv Drug Deliv Rev; 2016 Apr; 99(Pt A):28-51. PubMed ID: 26456916
[TBL] [Abstract][Full Text] [Related]
17. Engineering Well-Characterized PEG-Coated Nanoparticles for Elucidating Biological Barriers to Drug Delivery.
Yang Q; Lai SK
Methods Mol Biol; 2017; 1530():125-137. PubMed ID: 28150200
[TBL] [Abstract][Full Text] [Related]
18. Comprehensive study of the drug delivery properties of poly(l-lactide)-poly(ethylene glycol) nanoparticles in rats and tumor-bearing mice.
Shalgunov V; Zaytseva-Zotova D; Zintchenko A; Levada T; Shilov Y; Andreyev D; Dzhumashev D; Metelkin E; Urusova A; Demin O; McDonnell K; Troiano G; Zale S; Safarovа E
J Control Release; 2017 Sep; 261():31-42. PubMed ID: 28611009
[TBL] [Abstract][Full Text] [Related]
19. The Importance of Poly(ethylene glycol) Alternatives for Overcoming PEG Immunogenicity in Drug Delivery and Bioconjugation.
Hoang Thi TT; Pilkington EH; Nguyen DH; Lee JS; Park KD; Truong NP
Polymers (Basel); 2020 Feb; 12(2):. PubMed ID: 32024289
[TBL] [Abstract][Full Text] [Related]
20. Polyethylene Glycol Immunogenicity: Theoretical, Clinical, and Practical Aspects of Anti-Polyethylene Glycol Antibodies.
Chen BM; Cheng TL; Roffler SR
ACS Nano; 2021 Sep; 15(9):14022-14048. PubMed ID: 34469112
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
